A comprehensive review of HAE derived exclusively from the latest scientific literature

  Cinryze, ViroPharma's C1-Inh product, is FDA approved and can be prescribed to prevent HAE attacks
Please contact the HAEA's Patient Services group for more information:

Donna Davis donna-davis@haea.org, (808) 216-1029 or
Michelle Williamson michellewilliamson@haea.org, (972) 814-5205

The HAE Association culled the medical literature and distilled the latest thinking of HAE thought leaders into a "reference" compendium that can be used as a quick, but authoritative information source by clinicians who follow HAE patients.

HAE Overview

HAE Symptoms

HAE Attack Triggers

HAE Pathophysiology

Diagnosing HAE

Comprehensive Angioedema Typology and Description

HAE Treatments

HAE Clinical Trials Offer Hope for Better Therapies

UK Consensus Document
The UK Consensus document (see link below) can provide US clinicians with a definitive, reliable, scientifically-based overview of HAE genetics, pathophysiology, diagnosis, and treatment.

HAE in the News
Browse a collection of press releases on HAE.

If you are a medical professional wishing to be included in our database of physicians who treat HAE patients, please click here. We will use this database to refer HAE patients to physicians knowledgable about HAE diagnosis and treatments.

Misc. Resources

C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option
Economic and political factors have led to the increased use of home therapy programmes for patients who have traditionally been treated in hospital. Many patients with hereditary angioedema (HAE) experience intermittent severe aTtacks that affect their quality of life and may be life-threatening. These attacks are treated with C1-inhibitor concentrate which, for most patients, is infused at the local hospital. Home therapy programmes for HAE are currently being established. This paper reviews the extent of use of these programmes and summarizes the advantages and potential disadvantages of the concept so far.

CME Courses

Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies more...

New Directions in Angioedema more...


Do you have any questions?

Web Suggestions, Comments





HAEA.org is supported by grants from the following biotechnology companies:


















© 2007-2008 www.haea.org. All rights reserved.
HAEA.org is supported by grants from the following biotechnology companies:
CSL Behring, Dyax Corporation, Genzyme Corporation, Jerini AG, ViroPharma, and Pharming NV